Dr. Hofmeister Discusses Sequencing Treatment in Myeloma
In Partnership With:
Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses sequencing treatment in multiple myeloma.
Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses sequencing treatment in multiple myeloma.
General upfront treatment for myeloma is a proteasome inhibitor, immunomodulatory drug (IMiD), dexamethasone, and then transplant. From there, based on the patient’s risk profile, it is a 1- to 3-drug maintenance regimen.
At the time of relapse, monoclonal antibodies are showing excellent response rates in combination. As for the third- and fourth-line settings, agents are currently being tested but are showing significant side effects, says Hofmeister.
